Anticoagulants market: Key market research findings
- Novel oral anticoagulants (NOACs) to play a key role in the growth of the market
- Increase in the development of heparin drug in new therapeutic uses
- Key vendors in the anticoagulation market include Boehringer Ingelheim, BMS, Daiichi Sankyo, Johnson & Johnson, and Sanofi.
Technavio’s market research analysts estimate the anticoagulants market in the US to grow at a CAGR of almost 7% between 2016 and 2020. The increased acceptance of NOACs is the primary driver for the market. The rapid onset of action, inessential monitoring and better safety and efficacy profiles is augmenting the adoption rate of NOACs in the anticoagulants market. The increasing demand stemming from the growing prevalence of coagulation disorders and the surge in the number of surgical procedures in the US is likely to boost the growth of the market during the forecast period. At present, the oral anticoagulation segment dominates the anticoagulants market in the US by accounting for more than 59% of the overall market share. The approval of class of factor Xa inhibitors and direct thrombin inhibitors are likely to drive the growth of this segment by 2020.
The new market research report from Technavio presents a breakdown and analysis of the anticoagulants segments by drug class.
“The exploitation of Heparin and related drugs in new therapeutic uses is the latest trend in the anticoagulants market. Apart from their anticoagulant properties, Heparin exhibits anti-inflammatory activities and prevents the metastatic spread of tumor cells. Extensive research and studies are being carried out to exploit the use of heparin as an anti-inflammatory and antitumor agent. There is an increase in the development of heparin drugs as novel formulations and for the treatment of indicators as a result of frequent innovations,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
During 2015, the factor Xa inhibitors dominated the anticoagulants market in the US by holding around 42% of the total market. The factor Xa inhibitor drugs market occoupies almost 95% of the overall market. Janssen Pharmaceuticals, BMS, Pfizer, Daiichi Sankyo, and Mylan are the key vendors in the factor Xa inhibitors market in the US. The major products in the market include drugs such as Xarelto, Eliquis, Savaysa, and Arixtra.
The key vendors in the anticoagulants market in the US include Boehringer Ingelheim, BMS, Daiichi Sankyo, Johnson & Johnson, and Sanofi. The market is highly competitive with the presence of numerous small and large vendors. At present, the market is growing at a high pace because of the increased uptake of NOACs. Vendors are making investments in developing generic formulations for blood coagulation and other novel therapeutic areas. Recently, Daiichi Sankyo witnessed the approval of its oral anticoagulant, which has increased its market share considerably.
A more detailed analysis is available on the Technavio report, Anticoagulants Market in the US 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
